Wall Street Zen Downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to Sell

Reviva Pharmaceuticals (NASDAQ:RVPH) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Tuesday, April 21st. D. Boral Capital cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, Maxim Group downgraded Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Stock Performance

NASDAQ RVPH opened at $0.67 on Friday. The firm has a market cap of $8.79 million, a PE ratio of -0.17 and a beta of 0.56. Reviva Pharmaceuticals has a one year low of $0.26 and a one year high of $17.20. The firm’s fifty day moving average is $0.66 and its two-hundred day moving average is $3.69.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Research analysts predict that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

Institutional Trading of Reviva Pharmaceuticals

Several hedge funds have recently made changes to their positions in RVPH. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the first quarter valued at about $58,000. Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the period. XTX Topco Ltd acquired a new stake in Reviva Pharmaceuticals in the second quarter valued at about $31,000. Armistice Capital LLC purchased a new stake in Reviva Pharmaceuticals in the 2nd quarter valued at approximately $1,026,000. Finally, Lido Advisors LLC purchased a new stake in Reviva Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.